SYS-CON MEDIA Authors: Pat Romanski, Yeshim Deniz, Janakiram MSV, Liz McMillan, Elizabeth White

News Feed Item

AbbVie and Eisai Announce the Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA



TOKYO, June 11, 2018 - (JCN Newswire) - AbbVie GK, Eisai Co., Ltd. and Eisai's subsidiary for gastrointestinal diseases EA Pharma Co., Ltd.announced that the autoinjection delivery system for HUMIRA (generic name: adalimumab [recombinant], "HUMIRA"), HUMIRA for Subcutaneous Injection 40 mg Pen 0.4 mL and HUMIRA for Subcutaneous Injection 80 mg Pen 0.8 mL, was listed in the National Health Insurance Drug Price Standard on 30th May. AbbVie and Eisai have launched the products today. HUMIRA is a fully human anti-TNF-alpha monoclonal antibody formulation.

The newly launched pen-type auto-injector devices were developed to simplify the operation and reduce the burden on patients when performing self-injection. The rounded pen-type body of this product is designed to fit in the hands of even patients who have a weak grip and conceal the needle tip when injected. In addition to the lock function and autoinjection delivery system which allows for the full amount drug injection in about 10 seconds, it features injection start and end alert sounds and an inspection window. The pen-type auto-injector devices are filled with the same drug solution as the conventional pre-filled syringe devices(1).

HUMIRA is the world's first fully human anti-TNF-alpha monoclonal antibody and works by neutralizing TNF-alpha (tumor necrosis factor alpha), a protein that plays a central role in the inflammatory response of autoimmune diseases such as rheumatoid arthritis. HUMIRA is already used by one million patients in over one hundred countries.

AbbVie, Eisai and EA Pharma continue to promote and provide information on the proper use of HUMIRA while making further contributions to improve the quality of life of patients.

(1) HUMIRA for Subcutaneous Injection 40 mg Syringe 0.4 mL and HUMIRA for Subcutaneous Injection 80 mg Syringe 0.8 mL

About HUMIRA

HUMIRA is a fully human anti-TNF-alpha monoclonal antibody formulation. In Japan, it is approved for the indications of "the treatment of rheumatoid arthritis (including inhibition of the progression of structural damage), the treatment of plaque psoriasis, arthritic psoriasis, pustular psoriasis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis*, intestinal Behcet's disease, and non-infectious uveitis, posterior uveitis or panuveitis, induction and maintenance therapy for moderate to severely active Crohn's disease (limited to patients who have had an inadequate response to conventional therapy), and treatment of moderate to severe ulcerative colitis (limited to patients who have had an inadequate response to conventional therapy ).

*HUMIRA for Subcutaneous Injection 80 mg Syringe 0.8 mL and HUMIRA for Subcutaneous Injection 80 mg Pen 0.8 mL are yet to be approved for this indication.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com.

About EA Pharma

EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. for gastrointestinal disease area, was established in April 2016 by integration of the gastrointestinal business unit with more than 60 years' history of the Eisai Group and the gastrointestinal business unit of the Ajinomoto Group having amino acid as its business core. EA Pharma is a gastrointestinal specialty pharma with a full value chain covering R&D, logistics and sales & marketing. For more information on EA Pharma Co., Ltd., please see www.eapharma.co.jp/en.

About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Source: Eisai

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120




Copyright 2018 JCN Newswire . All rights reserved.

More Stories By ACN Newswire

Copyright 2008 ACN Newswire. All rights reserved. Republication or redistribution of ACN Newswire content is expressly prohibited without the prior written consent of ACN Newswire. ACN Newswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Docker and Kubernetes are key elements of modern cloud native deployment automations. After building your microservices, common practice is to create docker images and create YAML files to automate the deployment with Docker and Kubernetes. Writing these YAMLs, Dockerfile descriptors are really painful and error prone.Ballerina is a new cloud-native programing language which understands the architecture around it - the compiler is environment aware of microservices directly deployable into infra...
Only the most exceptional IBMers are appointed with the rare distinction of IBM Fellow, the highest technical honor in the company. Shankar has also received the prestigious Outstanding Technical Achievement Award three times - an accomplishment befitting only the most innovative thinkers. Shankar Kalyana is among the most respected strategists in the global technology industry. As CTO, with over 32 years of IT experience, Mr. Kalyana has architected, designed, developed, and implemented custom ...
At CloudEXPO Silicon Valley, June 24-26, 2019, Digital Transformation (DX) is a major focus with expanded DevOpsSUMMIT and FinTechEXPO programs within the DXWorldEXPO agenda. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of business. Only 12% still survive. Similar percentages are found throug...
10ZiG Technology is a leading provider of endpoints for a Virtual Desktop Infrastructure environment. Our fast and reliable hardware is VMware, Citrix and Microsoft ready and designed to handle all ranges of usage - from task-based to sophisticated CAD/CAM users. 10ZiG prides itself in being one of the only companies whose sole focus is in Thin Clients and Zero Clients for VDI. This focus allows us to provide a truly unique level of personal service and customization that is a rare find in th...
As you know, enterprise IT conversation over the past year have often centered upon the open-source Kubernetes container orchestration system. In fact, Kubernetes has emerged as the key technology -- and even primary platform -- of cloud migrations for a wide variety of organizations. Kubernetes is critical to forward-looking enterprises that continue to push their IT infrastructures toward maximum functionality, scalability, and flexibility. As they do so, IT professionals are also embr...

CloudBees, Inc., the hub of enterprise Jenkins and DevOps, today announced a major investment in Kubernetes technology across all areas of the business. CloudBees has made Kubernetes a key part of its lon...

Signs of a shift in the usage of public clouds are everywhere. Previously, as organizations outgrew old IT methods, the natural answer was to try the public cloud approach; however, the public platform alone is not a complete solution. Complaints include unpredictable/escalating costs and mounting security concerns in the public cloud. Ultimately, public cloud adoption can ultimately mean a shift of IT pains instead of a resolution. That's why the move to hybrid, custom, and multi-cloud will ...
The Japan External Trade Organization (JETRO) is a non-profit organization that provides business support services to companies expanding to Japan. With the support of JETRO's dedicated staff, clients can incorporate their business; receive visa, immigration, and HR support; find dedicated office space; identify local government subsidies; get tailored market studies; and more.
Signs of a shift in the usage of public clouds are everywhere Previously, as organizations outgrew old IT methods, the natural answer was to try the public cloud approach; however, the public platform alone is not a complete solutionThe move to hybrid, custom, and multi-cloud will become more and more prevalent At the heart of this technology trend exists a custom solution to meet the needs and concerns of these organizations, including compliance, security, and cost issues Blending Ser...
While a hybrid cloud can ease that transition, designing and deploy that hybrid cloud still offers challenges for organizations concerned about lack of available cloud skillsets within their organization. Managed service providers offer a unique opportunity to fill those gaps and get organizations of all sizes on a hybrid cloud that meets their comfort level, while delivering enhanced benefits for cost, efficiency, agility, mobility, and elasticity.
Serverless Computing or Functions as a Service (FaaS) is gaining momentum. Amazon is fueling the innovation by expanding Lambda to edge devices and content distribution network. IBM, Microsoft, and Google have their own FaaS offerings in the public cloud. There are over half-a-dozen open source serverless projects that are getting the attention of developers.
If you are part of the cloud development community, you certainly know about “serverless computing,” almost a misnomer. Because it implies there are no servers which is untrue. However the servers are hidden from the developers. This model eliminates operational complexity and increases developer productivity. We came from monolithic computing to client-server to services to microservices to the serverless model. In other words, our systems have slowly “dissolved” from monolithic to function-...
Docker is sweeping across startups and enterprises alike, changing the way we build and ship applications. It's the most prominent and widely known software container platform, and it's particularly useful for eliminating common challenges when collaborating on code (like the "it works on my machine" phenomenon that most devs know all too well). With Docker, you can run and manage apps side-by-side - in isolated containers - resulting in better compute density. It's something that many developer...
When a company wants to develop an application, it must worry about many aspects: selecting the infrastructure, building the technical stack, defining the storage strategy, configuring networks, setting up monitoring and logging, and on top of that, the company needs to worry about high availability, flexibility, scalability, data processing, machine learning, etc. Going to the cloud infrastructure can help you solving these problems to a level, but what if we have a better way to do things. ...
The KCSP program is a pre-qualified tier of vetted service providers that offer Kubernetes support, consulting, professional services and training for organizations embarking on their Kubernetes journey. The KCSP program ensures that enterprises get the support they're looking for to roll out new applications more quickly and more efficiently than before, while feeling secure that there's a trusted and vetted partner that's available to support their production and operational needs.